SIRT3 and Alzheimer disease: Our findings suggest that people with AD who have lower CSF nicotinamide also have higher plasma nicotinamide N-methyl transferase, thereby metabolizing nicotinamide before a measurable change in Sirt-mediated pTau231 reduction could take place, and simultaneously promoting additional Sirt3 acetylation.